Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies

K. Itoh, C. M. Balch, J. L. Murray, D. R. Parkinson, A. B. Markowitz, M. Talpaz, K. Lee, A. A. Zukiwski, M. I. Ross, S. S. Legha, K. Hayakawa, M. A. Salmeron, L. B. Augustus

Research output: Contribution to journalArticlepeer-review

Abstract

Immunological properties of melanoma TILs before and/or after IL-2-based biotherapies were investigated. TILs harvested before therapies, including those for adoptive transfer, proliferated well in culture with IL-2 and displayed cytotoxicity relatively restricted to autologous tumor cells. In contrast, TILs during or at the end of IL-2 based therapies did not proliferate in culture with IL-2. TILs from tumors even harvested 45 days after the end of IL-2 therapy modestly proliferated in culture with IL-2 and showed MHC-nonrestricted cytotoxicity. The number of live tumor cells that were yielded from melanomas during or at the end of IL-2-based therapies significantly decreased in all nine patients with metastatic melanomas, regardless of their clinical responses (2 PR, 2 MR, 2 SD, and 3 PD). Collectively, these results suggest that current IL-2-based therapies rsulted in both transient nonresponsiveness of TILs to Il-2 and transient decrease in the number of live tumour cells in most melanoma patients.

Original languageEnglish (US)
Pages (from-to)647-654
Number of pages8
JournalIn Vivo
Volume5
Issue number6
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies'. Together they form a unique fingerprint.

Cite this